2,434 active trials 1,273 recruiting 340 Phase 3 910 sponsors 343 changes in 30 days
198 trials changed in the last 30 days: 8 stopped, 60 with notable changes, 130 with minor changes only.
Trial terminated
Sponsor's reason: Genmab has decided to discontinue further clinical development of acasunlimab following strategic portfolio prioritization. The decision was not related to safety concerns.
GenmabPhase 2 NCT05117242 Registry history of NCT05117242 on ClinicalTrials.gov (opens the registry)
Updated
Trial terminated
Sponsor's reason: The decision is based only on the Sponsor's internal portfolio prioritization and resource management considerations and is not due to the investigational product's toxicity considerations.
Also in this update: Final enrollment: 3 participants — 3% of the 120 planned; Primary completion date changed from estimate of Sep 1, 2027 to Jan 30, 2026
SystImmune Inc.Phase 1 NCT06714617 Registry history of NCT06714617 on ClinicalTrials.gov (opens the registry)
Updated
Trial terminated
Sponsor's reason: Early termination was due to insufficient tumor uptake thought to be limited by the binding affinity of EGFR, The termination is not related to any safety or quality concerns.
Also in this update: Primary completion date changed from estimate of Jul 21, 2026 to May 13, 2026; Final enrollment: 6 participants (planned 12)
AstraZenecaPhase 1 NCT07500987 Registry history of NCT07500987 on ClinicalTrials.gov (opens the registry)
Updated
Trial terminated
Sponsor's reason: The research and development strategy was adjusted, so the research was suspended
Also in this update: Final enrollment: 18 participants (planned 66)
Shanghai Junshi Bioscience Co., Ltd.Phase 2 NCT06924606 Registry history of NCT06924606 on ClinicalTrials.gov (opens the registry)
Updated
Trial terminated
Sponsor's reason: Slow Accrual
Also in this update: Final enrollment: 5 participants — 5% of the 108 planned; Primary completion date changed from estimate of Apr 28, 2027 to Aug 13, 2026
Hackensack Meridian HealthPhase 2 NCT05715229 Registry history of NCT05715229 on ClinicalTrials.gov (opens the registry)
Updated
Withdrawn before enrolling
Sponsor's reason: Lack of funding
Roswell Park Cancer InstitutePhase 2 NCT06943664 Registry history of NCT06943664 on ClinicalTrials.gov (opens the registry)
Updated
Recruitment suspended
Sponsor's reason: Pending ICF update
Dwight OwenPhase 1 NCT06616623 Registry history of NCT06616623 on ClinicalTrials.gov (opens the registry)
Updated
Trial terminated
Sponsor's reason: Poor accrual.
Also in this update: Primary completion date changed from estimate of Jun 30, 2026 to Feb 28, 2025
Pennington Biomedical Research CenterNot specified NCT05937074 Registry history of NCT05937074 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Aug 2026 to Jun 2027
Also in this update: Enrollment closed, study ongoing; Final enrollment: 76 participants (planned 40)
Sichuan Baili Pharmaceutical Co., Ltd.Phase 2 NCT06498986 Registry history of NCT06498986 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Dec 2031 to Nov 2036
Also in this update: Trial sites expanded: 53 → 65 locations
AbbViePhase 2/3 NCT07005102 Registry history of NCT07005102 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Dec 31, 2026 to Oct 31, 2027
Also in this update: Enrollment increased: 292 → 473 participants; Completion pushed from Jun 1, 2027 to Mar 30, 2028
Bicara TherapeuticsPhase 1 NCT04429542 Registry history of NCT04429542 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Mar 13, 2026 to Feb 16, 2027
Bristol-Myers SquibbPhase 3 NCT06140836 Registry history of NCT06140836 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Oct 2027 to Oct 2028
Also in this update: Primary endpoint(s) modified; Sponsor changed: Qingdao Sino-Cell Biomedicine Co., Ltd. to Hangzhou Huasai Biomedicine Co., Ltd.
Hangzhou Huasai Biomedicine Co., Ltd.Phase 1 NCT07830342 Registry history of NCT07830342 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 28, 2026 to Oct 25, 2029
PfizerPhase 4 NCT05144997 Registry history of NCT05144997 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jun 1, 2026 to Dec 1, 2028
Also in this update: Enrollment reduced: 90 → 35 participants; Completion pushed from Dec 31, 2027 to Mar 1, 2029
Portage BiotechPhase 1/2 NCT04969315 Registry history of NCT04969315 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Jun 30, 2026 to Dec 31, 2026
OncoC4, Inc.Phase 1/2 NCT04140526 Registry history of NCT04140526 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to Jun 30, 2029
National Cancer Institute (NCI)Phase 3 NCT04181060 Registry history of NCT04181060 on ClinicalTrials.gov (opens the registry)
Changed
Primary completion pushed from Dec 31, 2026 to Apr 20, 2030
Also in this update: Enrollment increased: 470 → 540 participants; Completion pushed from Mar 21, 2028 to Jul 22, 2030
SystImmune Inc.Phase 1 NCT05983432 Registry history of NCT05983432 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 2026 to Aug 2027
Also in this update: Completion pushed from Aug 2027 to Aug 2028
The Methodist Hospital Research InstitutePhase 1 NCT06566443 Registry history of NCT06566443 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Sep 2026 to Sep 2030
Also in this update: Enrollment increased: 12400 → 14500 participants; Completion pushed from Dec 2027 to Sep 2031
AIO-Studien-gGmbHNot specified NCT02622581 Registry history of NCT02622581 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Summit TherapeuticsPhase 3 NCT05899608 Registry history of NCT05899608 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Study completion date changed from estimate of Oct 14, 2026 to Aug 24, 2026
Merck Sharp & Dohme LLCPhase 3 NCT04956692 Registry history of NCT04956692 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Final enrollment: 25 participants (planned 40)
Novartis PharmaceuticalsPhase 1/2 NCT07468071 Registry history of NCT07468071 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Trial sites expanded: 155 → 216 locations; Study completion date changed from estimate of Aug 31, 2027 to Aug 26, 2026
Hoffmann-La RochePhase 3 NCT02486718 Registry history of NCT02486718 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 3 NCT07183189 Registry history of NCT07183189 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Merck Sharp & Dohme LLCPhase 3 NCT06077760 Registry history of NCT06077760 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Nuvectis Pharma, Inc.Phase 1 NCT05873686 Registry history of NCT05873686 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 30, 2026 to Jul 15, 2026
EMD Serono Research & Development Institute, Inc.Phase 1/2 NCT05882734 Registry history of NCT05882734 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Sep 30, 2027 to Sep 2, 2026; Final enrollment: 79 participants (planned 270)
Incendia TherapeuticsPhase 1 NCT05753722 Registry history of NCT05753722 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 65 participants (planned 87)
Yonsei UniversityPhase 2 NCT05786430 Registry history of NCT05786430 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Jan 1, 2026 to Jun 1, 2026
JIANYANG WANGPhase 2 NCT07037680 Registry history of NCT07037680 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Final enrollment: 6 participants (planned 8)
Alpha Biopharma (Jiangsu) Co., Ltd.Phase 1 NCT07620951 Registry history of NCT07620951 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Radiopharm Theranostics, LtdPhase 1 NCT05799274 Registry history of NCT05799274 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
OncoC4, Inc.Phase 1 NCT05858736 Registry history of NCT05858736 on ClinicalTrials.gov (opens the registry)
Updated
Trial status changed: Recruiting → Enrolling by Invitation
Persephone BiosciencesNot specified NCT04291755 Registry history of NCT04291755 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Sun Yat-sen UniversityNot applicable NCT06524427 Registry history of NCT06524427 on ClinicalTrials.gov (opens the registry)
Updated
Trial status changed: Enrolling by Invitation → Active, Not Recruiting
Also in this update: Primary and study completion pushed from Jul 2026 to Nov 2026
Abramson Cancer Center at Penn MedicineNot specified NCT06332131 Registry history of NCT06332131 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 2026 to Dec 2026
ETOP IBCSG Partners FoundationPhase 2 NCT03965468 Registry history of NCT03965468 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Sep 2, 2026 to Dec 10, 2026
Boehringer IngelheimPhase 3 NCT06151574 Registry history of NCT06151574 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 15, 2026 to Dec 15, 2026
PMV Pharmaceuticals, IncPhase 1/2 NCT04585750 Registry history of NCT04585750 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
NRG OncologyPhase 3 NCT06500455 Registry history of NCT06500455 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 2026 to Mar 2027
Gilead SciencesPhase 2 NCT05186974 Registry history of NCT05186974 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 208 → 254 participants
Obsidian Therapeutics, Inc.Phase 1/2 NCT06060613 Registry history of NCT06060613 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to May 31, 2027
National Cancer Institute (NCI)Phase 3 NCT02595944 Registry history of NCT02595944 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
University of NebraskaPhase 1/2 NCT06579196 Registry history of NCT06579196 on ClinicalTrials.gov (opens the registry)
Updated
Sponsor refiled this as active, not recruiting (was completed)
Icahn School of Medicine at Mount SinaiPhase 2 NCT04123379 Registry history of NCT04123379 on ClinicalTrials.gov (opens the registry)
Updated
Trial completed
Also in this update: Primary completion date changed from estimate of Jun 7, 2028 to Sep 15, 2026
M.D. Anderson Cancer CenterPhase 1/2 NCT05017025 Registry history of NCT05017025 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 100 → 140 participants
Zymeworks BC Inc.Phase 1 NCT07164313 Registry history of NCT07164313 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to Mar 31, 2027
National Cancer Institute (NCI)Phase 2 NCT04310007 Registry history of NCT04310007 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 104 → 117 locations
And 3 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07513376 Registry history of NCT07513376 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 247 → 231 locations
Also in this update: Completion moved earlier from Feb 28, 2029 to Nov 12, 2027; Primary completion date changed from estimate of Feb 28, 2029 to Aug 17, 2026
AstraZenecaPhase 3 NCT05984277 Registry history of NCT05984277 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 91 → 95 locations
And 4 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07554339 Registry history of NCT07554339 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment closed, study ongoing
Also in this update: Primary completion pushed from Aug 1, 2026 to Nov 1, 2026
Universitaire Ziekenhuizen KU LeuvenNot applicable NCT07259447 Registry history of NCT07259447 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 31, 2026 to May 1, 2027
Mayo ClinicPhase 2 NCT06265285 Registry history of NCT06265285 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 17 → 22 locations
And 1 more change in the last 30 days
Astellas Pharma Global Development, Inc.Phase 3 NCT07566052 Registry history of NCT07566052 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Aug 2026 to Dec 2026
Stanford UniversityPhase 3 NCT04585490 Registry history of NCT04585490 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 479 → 484 locations
And 1 more change in the last 30 days
PfizerPhase 3 NCT07222566 Registry history of NCT07222566 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 56 → 52 locations
Servier Bio-Innovation LLCPhase 1/2 NCT06162572 Registry history of NCT06162572 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 444 → 555 participants
BayerPhase 3 NCT06452277 Registry history of NCT06452277 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 280 → 288 locations
Hoffmann-La RochePhase 3 NCT06793215 Registry history of NCT06793215 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 3 → 10 locations
And 1 more change in the last 30 days
Eli Lilly and CompanyPhase 4 NCT07822880 Registry history of NCT07822880 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 90 → 104 locations
And 4 more changes in the last 30 days
PfizerPhase 1/2 NCT07227298 Registry history of NCT07227298 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 29 → 37 locations
And 1 more change in the last 30 days
PfizerPhase 2 NCT07489066 Registry history of NCT07489066 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Nov 2026 to Feb 2027
Alliance Foundation Trials, LLC.Phase 2 NCT05798663 Registry history of NCT05798663 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 98 → 104 locations
NovoCure GmbHPhase 3 NCT06216301 Registry history of NCT06216301 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 76 → 102 participants
GI Innovation, Inc.Phase 1/2 NCT07172802 Registry history of NCT07172802 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 74 → 91 locations
GenmabPhase 2 NCT07288177 Registry history of NCT07288177 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 386 → 413 locations
SWOG Cancer Research NetworkPhase 2/3 NCT06616584 Registry history of NCT06616584 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Sep 1, 2027 to Jan 31, 2028
Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 1 NCT07140315 Registry history of NCT07140315 on ClinicalTrials.gov (opens the registry)
Updated
Enrollment increased: 167 → 190 participants
Also in this update: Primary completion date changed from estimate of Aug 3, 2028 to Jun 16, 2026
AstraZenecaPhase 1 NCT05647122 Registry history of NCT05647122 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion pushed from Oct 2026 to Dec 2026
Case Comprehensive Cancer CenterPhase 2 NCT07104630 Registry history of NCT07104630 on ClinicalTrials.gov (opens the registry)
Updated
Primary and study completion pushed from Dec 2028 to May 2029
Centre Antoine LacassagnePhase 4 NCT07633613 Registry history of NCT07633613 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 24 → 28 locations
Eikon TherapeuticsPhase 2/3 NCT07365319 Registry history of NCT07365319 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 215 → 218 locations
And 2 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07190248 Registry history of NCT07190248 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 8 → 25 locations
Olema Pharmaceuticals, Inc.Phase 1 NCT06784193 Registry history of NCT06784193 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 266 → 278 locations
SWOG Cancer Research NetworkPhase 2 NCT06031688 Registry history of NCT06031688 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 248 → 271 locations
SWOG Cancer Research NetworkPhase 2 NCT06116682 Registry history of NCT06116682 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 106 → 110 locations
And 2 more changes in the last 30 days
Merck Sharp & Dohme LLCPhase 3 NCT07431827 Registry history of NCT07431827 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 279 → 284 locations
Bristol-Myers SquibbPhase 3 NCT07361510 Registry history of NCT07361510 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 91 → 94 locations
Daiichi SankyoPhase 2 NCT06172478 Registry history of NCT06172478 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 83 → 96 locations
And 3 more changes in the last 30 days
National Cancer Institute (NCI)Phase 3 NCT07388524 Registry history of NCT07388524 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 153 → 158 locations
Revolution Medicines, Inc.Phase 3 NCT06881784 Registry history of NCT06881784 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 431 → 449 locations
PfizerPhase 3 NCT07144280 Registry history of NCT07144280 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 372 → 389 locations
PfizerPhase 3 NCT06758401 Registry history of NCT06758401 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 295 → 300 locations
AstraZenecaPhase 3 NCT06627647 Registry history of NCT06627647 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 262 → 365 locations
BioNTech SEPhase 2/3 NCT06712316 Registry history of NCT06712316 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 325 → 328 locations
AstraZenecaPhase 3 NCT06692738 Registry history of NCT06692738 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 274 → 285 locations
Summit TherapeuticsPhase 3 NCT06767514 Registry history of NCT06767514 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 110 → 116 locations
AbbViePhase 2/3 NCT07155187 Registry history of NCT07155187 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 237 → 242 locations
Daiichi SankyoPhase 3 NCT06899126 Registry history of NCT06899126 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 322 → 326 locations
Bristol-Myers SquibbPhase 3 NCT06561386 Registry history of NCT06561386 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 414 → 418 locations
AmgenPhase 3 NCT05920356 Registry history of NCT05920356 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 8 → 12 locations
ALX Oncology Inc.Phase 1 NCT07085091 Registry history of NCT07085091 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites reduced: 23 → 20 locations
AstraZenecaPhase 1 NCT05877599 Registry history of NCT05877599 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 20 → 23 locations
Janssen Research & Development, LLCPhase 2 NCT07586202 Registry history of NCT07586202 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 3 → 16 locations
Blueprint Medicines CorporationPhase 1/2 NCT07629960 Registry history of NCT07629960 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 35 → 40 locations
Maia BiotechnologyPhase 2 NCT05208944 Registry history of NCT05208944 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 18 → 29 locations
Gilead SciencesPhase 1/2 NCT06303505 Registry history of NCT06303505 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 15 → 20 locations
PfizerPhase 1 NCT07519655 Registry history of NCT07519655 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 0 → 7 locations
PfizerPhase 1 NCT07663630 Registry history of NCT07663630 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 17 → 20 locations
IDEAYA BiosciencesPhase 1 NCT07277413 Registry history of NCT07277413 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Dec 31, 2026 to Nov 30, 2027
Also in this update: Primary completion date changed from estimate of Dec 31, 2026 to Nov 30, 2025
Klus Pharma Inc.Phase 1/2 NCT04152499 Registry history of NCT04152499 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 2 → 47 locations
Paradigm HealthNot specified NCT06605404 Registry history of NCT06605404 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 8 → 11 locations
N-Power MedicineNot specified NCT07174388 Registry history of NCT07174388 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Dec 31, 2026 to Oct 28, 2026
Novartis PharmaceuticalsPhase 2 NCT05445843 Registry history of NCT05445843 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 467 → 486 locations
Wake Forest University Health SciencesNot specified NCT06418204 Registry history of NCT06418204 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 97 → 111 locations
Alliance for Clinical Trials in OncologyPhase 2 NCT07293247 Registry history of NCT07293247 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 1 → 4 locations
Nantes University HospitalNot applicable NCT06481813 Registry history of NCT06481813 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
Also in this update: Start date changed from estimate of Aug 31, 2026 to Sep 10, 2026; and 1 more change in the last 30 days
Bristol-Myers SquibbPhase 2 NCT07680764 Registry history of NCT07680764 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 8 → 11 locations
H. Lee Moffitt Cancer Center and Research InstitutePhase 2 NCT06745882 Registry history of NCT06745882 on ClinicalTrials.gov (opens the registry)
Updated
Trial sites expanded: 27 → 49 locations
Institut de Recherches Internationales ServierPhase 1/2 NCT05786924 Registry history of NCT05786924 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
ExelixisPhase 1 NCT05176483 Registry history of NCT05176483 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Jun 30, 2027 to Mar 31, 2027
Also in this update: Primary completion date changed from estimate of Jun 30, 2027 to Jul 10, 2026
AstraZenecaPhase 3 NCT06564844 Registry history of NCT06564844 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Nov 30, 2027 to Jul 3, 2028
Janssen Research & Development, LLCPhase 3 NCT04988295 Registry history of NCT04988295 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Jul 14, 2027 to Nov 25, 2026
Boehringer IngelheimPhase 1 NCT05068102 Registry history of NCT05068102 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Mar 31, 2027 to Sep 30, 2027
Janssen Research & Development, LLCPhase 2 NCT05663866 Registry history of NCT05663866 on ClinicalTrials.gov (opens the registry)
Updated
Completion moved earlier from Jun 7, 2029 to Nov 30, 2027
Johnson & Johnson Enterprise Innovation Inc.Phase 1 NCT06116786 Registry history of NCT06116786 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Dec 31, 2026 to Dec 31, 2027
Janssen Research & Development, LLCPhase 1 NCT02609776 Registry history of NCT02609776 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Dec 23, 2026 to Apr 15, 2026
USWM CT, LLCPhase 1 NCT04044859 Registry history of NCT04044859 on ClinicalTrials.gov (opens the registry)
Updated
Start date changed from estimate of Sep 22, 2026 to Sep 8, 2026
Novartis PharmaceuticalsPhase 1 NCT07801508 Registry history of NCT07801508 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Jul 2026 to Jun 2027
H. Lee Moffitt Cancer Center and Research InstitutePhase 1/2 NCT02638090 Registry history of NCT02638090 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 1, 2026 to Feb 1, 2027
SWOG Cancer Research NetworkNot specified NCT03939481 Registry history of NCT03939481 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
Also in this update: Primary completion date changed from estimate of Sep 2027 to Dec 31, 2024
Xiangya Hospital of Central South UniversityPhase 2 NCT04699721 Registry history of NCT04699721 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Dec 31, 2026 to Jun 30, 2027
Ohio State University Comprehensive Cancer CenterNot applicable NCT07584239 Registry history of NCT07584239 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Jan 2027 to Sep 23, 2026
University of Colorado, DenverPhase 1/2 NCT05845671 Registry history of NCT05845671 on ClinicalTrials.gov (opens the registry)
Updated
Completion pushed from Sep 28, 2026 to Sep 21, 2027
Also in this update: Primary completion date changed from estimate of Sep 28, 2026 to Dec 3, 2025; Final enrollment: 7458 participants (planned 8300)
National Cancer Institute (NCI)Not applicable NCT02194738 Registry history of NCT02194738 on ClinicalTrials.gov (opens the registry)
Updated
Primary completion date changed from estimate of Sep 2, 2026 to Apr 30, 2026
Emory UniversityPhase 2 NCT04340882 Registry history of NCT04340882 on ClinicalTrials.gov (opens the registry)
Updated
Interventions modified
Washington University School of MedicinePhase 1 NCT06529822 Registry history of NCT06529822 on ClinicalTrials.gov (opens the registry)
Updated
Registry marked status Unknown (sponsor has not verified the record since Jun 2024); last known: Active, Not Recruiting
Jiangsu Aosaikang Pharmaceutical Co., Ltd.Phase 3 NCT04143607 Registry history of NCT04143607 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Shanghai Hengrui Pharmaceutical Co., Ltd.Phase 1/2 NCT06589778 Registry history of NCT06589778 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Light Chain Bioscience - Novimmune SAPhase 1 NCT05403554 Registry history of NCT05403554 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Dec 2023); last known: Recruiting
Ningbo Medical Center Lihuili HospitalNot applicable NCT06188650 Registry history of NCT06188650 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Hunan Province Tumor HospitalPhase 2 NCT06537297 Registry history of NCT06537297 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Recruiting
Changhai HospitalPhase 2 NCT06394674 Registry history of NCT06394674 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hunan Province Tumor HospitalPhase 2 NCT05379803 Registry history of NCT05379803 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hunan Province Tumor HospitalPhase 2 NCT05295212 Registry history of NCT05295212 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Yongchang ZhangPhase 2 NCT04144569 Registry history of NCT04144569 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Second Affiliated Hospital of Xi'an Jiaotong UniversityNot specified NCT06757114 Registry history of NCT06757114 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Active, Not Recruiting
National Taiwan University HospitalNot applicable NCT06616909 Registry history of NCT06616909 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Xuanwu Hospital, BeijingNot applicable NCT06607926 Registry history of NCT06607926 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Yousheng MaoNot applicable NCT06598839 Registry history of NCT06598839 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Not Yet Recruiting
Shanghai East HospitalNot specified NCT06586801 Registry history of NCT06586801 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Aug 2024); last known: Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCSNot specified NCT06532149 Registry history of NCT06532149 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Oct 2023); last known: Not Yet Recruiting
Daping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityNot specified NCT06117644 Registry history of NCT06117644 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hunan Province Tumor HospitalNot specified NCT05991193 Registry history of NCT05991193 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Nov 2023); last known: Recruiting
Ruijin HospitalNot applicable NCT05557552 Registry history of NCT05557552 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Yongchang ZhangNot specified NCT04777175 Registry history of NCT04777175 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hunan Province Tumor HospitalNot specified NCT04324125 Registry history of NCT04324125 on ClinicalTrials.gov (opens the registry)
Changed
Registry marked status Unknown (sponsor has not verified the record since Sep 2024); last known: Recruiting
Hunan Province Tumor HospitalNot specified NCT04324151 Registry history of NCT04324151 on ClinicalTrials.gov (opens the registry)
Changed
Registry verification sweep
Changed
Primary completion date changed from estimate of Mar 2027 to Jul 2, 2026
H. Lee Moffitt Cancer Center and Research InstituteNot applicable NCT06337552 Registry history of NCT06337552 on ClinicalTrials.gov (opens the registry)
Updated
| First posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-10-08 | NCT07864584 Study Using a Drug-device Combination Product to Determine Safety, Tolerability and… | Nob Hill Therapeutics, Inc. new | Phase 1/2 |
| 2026-09-24 | NCT07838532 Real-World Study of Aumolertinib in Patients With Advanced EGFR T790M-Positive NSCLC | Xin Li new | |
| 2026-09-23 | NCT07836543 Trastuzumab Rezetecan and Adebrelimab, Alone or in Combination, After Chemoradiotherapy… | Ming Chen new | Phase 2 |
| 2026-09-22 | NCT07833202 A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for… | Shanghai Jeyou Pharmaceutical Co., Ltd. new | Phase 3 |
| 2026-09-21 | NCT07831863 A Study of 7MW3711 Compared With Docetaxel in Advanced Squamous NSCLC After Prior… | Mabwell (Shanghai) Bioscience Co., Ltd. new | Phase 3 |
| 2026-09-18 | NCT07828938 Short- and Mid-term Therapeutic, Prognostic, and Societal Impact of Implementing… | Fondation Hôpital Saint-Joseph new | |
| 2026-09-16 | NCT07823855 SIB Accelerated Hyperfractionated RT for High-Proliferation NSCLC | Second Affiliated Hospital, Zhejiang University, School of Medicine new | |
| 2026-09-16 | NCT07823725 TailorDose Lung: Decentralized TDM of Taxanes and ALK Inhibitors Using Capillary… | Karolinska Institutet new | |
| 2026-09-15 | NCT07819578 Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLC | Shaodong Hong new | Phase 2 |
| 2026-09-14 | NCT07817329 NUT Project: Nutritional Support in Thoracic Oncology | Casa di Cura Dott. Pederzoli new |
| Early Phase 1 | 24 | |
| Phase 1 | 343 | |
| Phase 1/2 | 285 | |
| Phase 2 | 763 | |
| Phase 2/3 | 44 | |
| Phase 3 | 296 | |
| Phase 4 | 30 |
| NCT ID | Title | Sponsor | Status | Updated |
|---|---|---|---|---|
| Phase 4 | ||||
| NCT03340506 | Dabrafenib and/or Trametinib Rollover Study | Novartis Pharmaceuticals | Recruiting | 2026-10-09 |
| NCT07279935 | Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After… | AstraZeneca | Recruiting | 2026-08-27 |
| NCT06908070 | Chemoradiotherapy With Surgery Followed by Consolidation Durvalumab | Idris Bahce | Recruiting | 2026-08-20 |
| NCT07704658 | Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors | Rigel Pharmaceuticals | Recruiting | 2026-08-10 |
| NCT07754812 | Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment… | Shanghai Pulmonary Hospital, Shanghai, China | Recruiting | 2026-08-10 |
| NCT07744698 | Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer… | Anhui Provincial Cancer Hospital | Recruiting | 2026-08-04 |
| NCT07405086 | Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or… | OHSU Knight Cancer Institute | Recruiting | 2026-06-12 |
| NCT06646471 | PROspective Master-protocol for Evaluation of Systemic THErapeutics in Elderly With… | GFPC Investigation | Recruiting | 2026-04-29 |
| NCT06330038 | Anesthesia and Non-small Cell Lung Cancer Recurrence | Samsung Medical Center | Recruiting | 2026-04-20 |
| NCT07320105 | Postoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy… | Fujian Cancer Hospital | Recruiting | 2026-01-06 |
| NCT07092202 | Firmonertinib Combined With Intrathecal Injection for the Treatment of EGFR Mutant NSCLC… | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Recruiting | 2025-07-29 |
| NCT05525338 | Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib… | University Medical Center Groningen | Recruiting | 2024-05-13 |
| NCT05172739 | Opioid Free Anaesthesia-Analgesia Strategy on Surgical Stress and Immunomodulation in… | University of Crete | Recruiting | 2021-12-29 |
| NCT07822880 | A Study of Selpercatinib (LY3527723) in Participants With Rearranged During Transfection… | Eli Lilly and Company | Not Yet Recruiting | 2026-10-08 |
| NCT07843251 | A Prospective Trial Evaluating the Efficacy and Tumor Immune Microenvironment Remodeling… | Anhui Provincial Cancer Hospital | Not Yet Recruiting | 2026-09-28 |
| NCT05144997 | Lorlatinib Continuation Study | Pfizer | Active, Not Recruiting | 2026-09-23 |
| NCT07633613 | Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor… | Centre Antoine Lacassagne | Not Yet Recruiting | 2026-09-15 |
| NCT07768358 | Tucatinib Continuation Study | Pfizer | Not Yet Recruiting | 2026-08-28 |
| NCT07674368 | Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed | Hunan Cancer Hospital | Not Yet Recruiting | 2026-07-01 |
| NCT07671560 | Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant… | Qiming Wang | Not Yet Recruiting | 2026-06-26 |
| NCT07567313 | Stage IV Lung Squamous Cell Carcinoma Treated With or Without Bronchial Artery… | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Not Yet Recruiting | 2026-05-05 |
| NCT06282874 | Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases | Guangdong Association of Clinical Trials | Active, Not Recruiting | 2026-04-09 |
| NCT05160922 | Crizotinib Continuation Clinical Study | Pfizer | Active, Not Recruiting | 2026-03-30 |
| NCT07469488 | A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM)… | Shanghai Pulmonary Hospital, Shanghai, China | Not Yet Recruiting | 2026-03-13 |
| NCT05689671 | Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung… | Nikolaj Frost MD | Active, Not Recruiting | 2026-03-10 |
AstraZeneca (78) · National Cancer Institute (NCI) (46) · Shanghai Pulmonary Hospital, Shanghai, China (42) · Sun Yat-sen University (38) · Fudan University (36) · M.D. Anderson Cancer Center (32) · Shanghai Chest Hospital (32) · Tianjin Medical University Cancer Institute and Hospital (28) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (25) · Merck Sharp & Dohme LLC (25)